May 21, 2009 (FinancialWire) — biOasis Technologies Inc. (TSX Venture: BTI) has entered into a collaborative research agreement with The University of British Columbia to develop a test help diagnose Alzheimer’s disease.

Additionally, this test may also be used to monitor the effectiveness of therapeutics used to treat the disease. Standard operating procedures will be developed around the assay, which will be supplied for distribution to clinical laboratories as part of the license terms with BTI.

Other objectives of the CRA are to correlate the presence of “p97″ in tissues with other markers of Alzheimer’s disease, such as the presence of senile plaques, and to correlate the expression of p97 with other markers of Alzheimer’s disease, from human bioinformatic databases.

biOasis Technologies Inc. is a Canadian biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.